DrugPatentWatch Database Preview
ZAGAM Drug Profile
or, see our see our flat-rate plans
When do Zagam patents expire, and when can generic versions of Zagam launch?
The generic ingredient in ZAGAM is sparfloxacin. Additional details are available on the sparfloxacin profile page.
Summary for ZAGAM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 65 |
| Patent Applications: | 3,425 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ZAGAM at DailyMed |
Synonyms for ZAGAM
| (cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
| 110871-86-8 |
| 111542-93-9 |
| 3-Quinolinecarboxylic acid, 1,4-dihydro-5-amino-1-cyclopropyl-6,8-difluoro-7-(3,5-dimethyl-1-piperazinyl)-4-oxo-, cis- |
| 3-Quinolinecarboxylic acid, 5-amino-1-cyclopropyl-7-((3R,5S)-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, rel- |
| 3-Quinolinecarboxylic acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, cis- |
| 3-Quinolinecarboxylic acid, 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-6,8-difluoro-1,4-dihydro-4-oxo-, rel- |
| 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
| 5-amino-1-cyclopropyl-6,8-difluoro-7-(cis-3,5-dimethyl-1-piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid |
| 5-amino-1-cyclopropyl-7-((3R,5S)-3,5-dimethylpiperazin-1-yl)-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| 5-amino-1-cyclopropyl-7-((3S,5R)-3,5-dimethylpiperazin-1-yl)-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)- 6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
| 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
| 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic Acid |
| 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555 |
| 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555 |
| 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-quinoline-3-carboxylic acid |
| 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid |
| 5-amino-1-cyclopropyl-7-[(3S,5R)-3,5-dimethyl-1-piperazinyl]-6,8-difluoro-4-oxo-3-quinolinecarboxylic acid |
| 5-amino-1-cyclopropyl-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-quinoline-3-carboxylic acid |
| 5-amino-1-cyclopropyl-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid |
| 5-azanyl-1-cyclopropyl-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-6,8-bis(fluoranyl)-4-oxidanylidene-quinoline-3-carboxylic acid |
| 871S868 |
| A802376 |
| AB00639950_03 |
| AB00639950-02 |
| AC-11574 |
| AC1L1TB5 |
| AC1Q29E9 |
| AJ-23393 |
| AK115680 |
| AKOS005622503 |
| AN-33527 |
| API0004214 |
| AT 4140 |
| AT-4140 |
| AX8151779 |
| BB_SC-1127 |
| BBL010957 |
| BDBM50366822 |
| BRN 3658018 |
| C07662 |
| CAS-110871-86-8 |
| CCG-221166 |
| CHEBI:9212 |
| CHEMBL850 |
| CI 978 |
| CI-978 |
| cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
| CP 103826 |
| CP-103826 |
| CPD000466312 |
| CS-2347 |
| D00590 |
| D0K6GZ |
| DB01208 |
| DRG-0143 |
| DSSTox_CID_3590 |
| DSSTox_GSID_23590 |
| DSSTox_RID_77097 |
| DTXSID9023590 |
| DZZWHBIBMUVIIW-DTORHVGOSA-N |
| Epitope ID:119065 |
| Esparfloxacino |
| Esparfloxacino [INN-Spanish] |
| FT-0631055 |
| FT-0674635 |
| HE066359 |
| HE295402 |
| HMS2090N19 |
| HY-B0308 |
| I06-1320 |
| KB-291851 |
| KS-5009 |
| Liposome-encapsulated sparfloxacin |
| LS-141521 |
| MCULE-1827276157 |
| MFCD00869619 |
| MLS000759417 |
| MolPort-002-507-759 |
| NCGC00159333-02 |
| NCGC00166294-01 |
| NCGC00166294-02 |
| NCGC00166294-03 |
| Parox |
| PD 1315-1 |
| PD 131501 |
| PD-131501 |
| PD131501 |
| Q90AGA787L |
| Respipac (TN) |
| RP-64206 |
| RT-015760 |
| S0896 |
| s1884 |
| SAM001246566 |
| SC-96745 |
| SCHEMBL41311 |
| SMR000466312 |
| Spara |
| sparcin |
| sparfloxacin |
| Sparfloxacin (JAN/USAN/INN) |
| Sparfloxacin [USAN:BAN:INN:JAN] |
| Sparfloxacin [USAN:INN:BAN:JAN] |
| Sparfloxacin & RU 40555 |
| Sparfloxacin trihydrate |
| Sparfloxacin, >=98.0% (HPLC) |
| Sparfloxacin, Antibiotic for Culture Media Use Only |
| sparfloxacin, cis-isomer |
| Sparfloxacin, VETRANAL(TM), analytical standard |
| Sparfloxacine |
| Sparfloxacine [INN-French] |
| Sparfloxacinum |
| Sparfloxacinum [INN-Latin] |
| SPFX |
| SR-01000759357 |
| SR-01000759357-2 |
| ST24031663 |
| STK802067 |
| Tox21_111580 |
| Tox21_111580_1 |
| UNII-Q90AGA787L |
| Zagam (TN) |
| ZINC538362 |
US Patents and Regulatory Information for ZAGAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan | ZAGAM | sparfloxacin | TABLET;ORAL | 020677-001 | Dec 19, 1996 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
Expired US Patents for ZAGAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mylan | ZAGAM | sparfloxacin | TABLET;ORAL | 020677-001 | Dec 19, 1996 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
or, see our see our flat-rate plans
